Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

379 ARTÍCULOS , VIENDO DEL 226 AL 240

Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2

Flynn Longmire CV, Drye LT, Frangakis CE, Martin BK, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG; DIADS-2 Research Group.

Am J Geriatr Psychiatry. 2014 Jan;22(1):14-24. doi: 10.1016/j.jagp.2013.02.014.

[Long-term antipsychotics for patients with dementia - discontinue or continue treatment?]

Renard D, de Pélichy E, von Elm E.

Praxis (Bern 1994). 2014 Jan 15;103(2):109-10. doi: 10.1024/1661-8157/a001543.

Butyrylcholinesterase K and apolipoprotein ε4 affect cortical thickness and neuropsychiatric symptoms in Alzheimer's disease

Yoo HB, Lee HW, Shin S, Park SW, Choi JS, Jung HY, Cha J, Lee JM, Lee JY.

Curr Alzheimer Res. 2014 Feb;11(2):137-44. doi: 10.2174/1567205011666140130152114.

A pilot study on the use of interferon beta-1a in early Alzheimer's disease subjects

Grimaldi LM, Zappalà G, Iemolo F, Castellano AE, Ruggieri S, Bruno G, Paolillo A.

J Neuroinflammation. 2014 Feb 13;11:30. doi: 10.1186/1742-2094-11-30.

Cholinesterase-inhibitor Associated Mania: A Case Report and Literature Review

Jalal H, Ganesh A, Lau R, Lysack J, Ismail Z.

Can J Neurol Sci. 2014 Mar;41(2):278-80. doi: 10.1017/s0317167100016735.

Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis

Alva G, Isaacson R, Sadowsky C, Grossberg G, Meng X, Somogyi M.

Int J Geriatr Psychiatry. 2014 Sep;29(9):920-7. doi: 10.1002/gps.4080. Epub 2014 Feb 18.

Sustained 4-year cognitive and functional response in early Alzheimer's disease with pioglitazone

Read S, Wu P, Biscow M.

J Am Geriatr Soc. 2014 Mar;62(3):584-6. doi: 10.1111/jgs.12722.

Does the evidence say a 4-point change in ADAS-cog score is clinically significant?

Oremus M.

Alzheimers Dement. 2014 May;10(3):416-7. doi: 10.1016/j.jalz.2013.12.017. Epub 2014 Mar 12.

Metal complexes designed to bind to amyloid-β for the diagnosis and treatment of Alzheimer's disease

Hayne DJ, Lim S, Donnelly PS.

Chem Soc Rev. 2014 Oct 7;43(19):6701-15. doi: 10.1039/c4cs00026a. Epub 2014 Mar 27.

Apathy in Alzheimer's disease: any effective treatment?

Rea R, Carotenuto A, Fasanaro AM, Traini E, Amenta F.

ScientificWorldJournal. 2014 Feb 2;2014:421385. doi: 10.1155/2014/421385. eCollection 2014.

Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan

Nakamura Y, Kitamura S, Homma A, Shiosakai K, Matsui D.

Expert Opin Pharmacother. 2014 May;15(7):913-25. doi: 10.1517/14656566.2014.902446. Epub 2014 Mar 27.

Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease

Carman AJ, Dacks PA, Lane RF, Shineman DW, Fillit HM.

J Nutr Health Aging. 2014 Apr;18(4):383-92. doi: 10.1007/s12603-014-0021-7.

Nanocarrier-based approaches for treatment and detection of Alzheimer's disease

Oesterling BM, Gulati A, Joshi MD.

J Nanosci Nanotechnol. 2014 Jan;14(1):137-56. doi: 10.1166/jnn.2014.8906.

Psychometric properties of the Dependence Scale in large randomized clinical trials of patients with mild and moderate Alzheimer's disease

Wyrwich KW, Auguste P, Buchanan J, Rudell K, Lacey L, Leibman C, Symonds T, Brashear HR.

Am J Alzheimers Dis Other Demen. 2014 Nov;29(7):620-9. doi: 10.1177/1533317514527336. Epub 2014 Apr 15.

A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease

Schwam EM, Nicholas T, Chew R, Billing CB, Davidson W, Ambrose D, Altstiel LD.

Curr Alzheimer Res. 2014;11(5):413-21. doi: 10.2174/1567205011666140505100858.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias